General Assembly And Dinner
December 7, 2012 - Creative Investments and Partnerships To Stimulate Innovation
Alan Paau, CLP, MBA, PhD
Vice Provost, Cornell University
President, Cornell Research Foundation, Inc.
Executive Director, Cornell Center for Technology Enterprise and Commercialization
President, New York City Economic Development Corporation
Greg Wiederrecht, Ph.D.
Vice President & Head of External Scientific Affairs
Worldwide Licensing & Acquisitions, Merck & Co.,Inc.
Tadataka Yamada, M.D.
Executive Vice President and Board Member
Chief Medical & Scientific Officer, Takeda Pharmaceuticals
James Greenwood (moderator)
President & CEO, Biotechnology Industry Organization
- Mr. Greenwood will give an overview of the topic, and present his own perspective as head of the world’s largest biotechnology industry organization.
- Dr. Yamada will discuss Takeda's efforts to form collaborations and partnerships to accelerate innovation. In addition, based on his former experiences heading the Bill & Melinda Gates Foundation Global Health Program and prior to that, as Chairman, R&D, and a Member of the Board of GlaxoSmithKline, he will provide a “big picture” perspective on how public/private partnerships can foster innovation globally in the area of medicine and life science.
- Dr. Wiederrecht will discuss three recent initiatives Merck launched to access innovation in the early space: (1) the Merck Research Venture Fund; (2) the California Institute of Biomedical Research; and the Merck Initiative on New Targets.
- Dr. Paau will discuss how Cornell uses its life science technology transfer program to move academic innovation to the next level by collaborating with government and commercial partners. He will explain Cornell’s well-established mechanisms for developing partnerships aimed at monetizing scientific innovation and maximize the chances for success in an environment where 90 percent of life science startups fail.
- Mr. Pinsky will discuss New York City’s biotech cluster initiative, the city’s partnership with Cornell, what the city hopes to accomplish from the project, what the city can offer in terms of life sciences funding, and what is unique and attractive in New York that will draw the biophamra industry.